Fenebrutinib (GDC-0853, RG7845): An Orally Administered Bruton's tyrosine Kinase (BTK) Inhibitor Designed to Block B Cell Proliferation - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com